|
JP2004244425A
|
|
Synthetic intermediate for hymenialdisine and its derivative
|
|
US2004202714A1
|
|
Oral pharmaceutical composition
|
|
JP2005239696A
|
|
Medicinal hard capsule preparation blended with inorganic substance
|
|
CA2515396A1
|
|
New glycolipids and synthetic method thereof as well as their synthetic intermediates,and synthetic method thereof
|
|
US2004208906A1
|
|
Pharmaceutical composition for topical administration
|
|
WO2004058295A1
|
|
Remedy for pemphigoid
|
|
BR0306685A
|
|
Pharmaceutical composition containing ghrelin
|
|
JP2004002378A
|
|
Method for producing modified peptide
|
|
AU2003213338A1
|
|
Tablet containing pilsicainide hydrochloride (dry)
|
|
AU2003213337A1
|
|
Tablet containing pilsicainide hydrochloride (wet)
|
|
WO03057241A1
|
|
Agents promoting the proliferation and/or differentiation of hematopoietic stem cells and/or hematopoietic precursor cells
|
|
WO03053975A1
|
|
Pyrazolopyrimidinone derivatives having pde7-inhibitory activity
|
|
CN1596120A
|
|
Medicinal compositions for nasal absorption
|
|
CA2429005A1
|
|
Substituted benzoic acid derivatives having nf-kb inhibiting action
|
|
CA2451138A1
|
|
Remedies for eosinophilic diseases
|
|
WO02097435A2
|
|
Assay method for platelet-activating factor
|
|
EP1314712A1
|
|
Nf-kappa-b inhibitor containing substituted benzoic acid derivative as active ingredient
|
|
JP2003277265A
|
|
PROPHYLACTIC OR THERAPEUTIC DRUG AGAINST DISEASE CAUSED BY eNOS EXPRESSION
|
|
CA2438590A1
|
|
Therapeutic methods and agents for diseases associated with decreased expression of aop-1 gene or aop-1
|
|
CA2431711A1
|
|
Remedies for heart failure
|
